Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for Stage IIIA-N2 non-small-cell lung cancer

World Journal of Surgery

Volumn 36, Issue 5, 2012, Pages 1199-1205

  Cho, Jong Ho ^a   Kim, Jhingook ^b   Kim, Kwhanmien ^b   Shim, Young Mog ^b   Kim, Hong Kwan ^b   Choi, Yong Soo ^b  

^a Korea University Ansan Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; EVALUATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; RISK; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84863726907     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1472-9     Document Type: Article

References (23)

1. Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706-714
2. Park BB, Park JO, Kim H et al (2006) Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 53:323-330
3. Albain KS, Swann RS, Rusch VW et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III nonsmall-cell lung cancer: a phase III randomised controlled trial. Lancet 374:379-386
4. Kappers I, van Sandick JW, Burgers SA et al (2010) Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided. Lung Cancer 68:222-227
5. Kim KJ, Ahn YC, Lim do H et al (2007) Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer 55:329-336
6. Johnstone DW, Byhardt RW, Ettinger D et al (2002) Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with nonsmall-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54:365-369
7. Thomas M, Rube C, Hoffknecht P et al (2008) Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9:636-648
8. Eberhardt W, Wilke H, Stamatis G et al (1998) Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16:622-634
9. Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945
10. Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year followup of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215
11. Sause WT, Scott C, Taylor S et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205
12. Nagai K, Tsuchiya R, Mori T et al (2003) A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125:254-260
13. Martini N, Kris MG, Flehinger BJ et al (1993) Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55:1365-1373 discussion 1373-1364
14. Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26:7-14
15. Betticher DC, Hsu Schmitz SF, Totsch M et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94:1099-1106
16. Massard G, Dabbagh A, Dumont P et al (1995) Are bilobectomies acceptable procedures? Ann Thorac Surg 60:640-645
17. Keller SM, Kaiser LR, Martini N (1988) Bilobectomy for bronchogenic carcinoma. Ann Thorac Surg 45:62-65
18. Deneuville M, Regnard JF, Coggia M et al (1992) The place for bilobectomy in bronchogenic carcinoma. Eur J Cardiothorac Surg 6:446-451
19. Demir A, Gunluoglu MZ, Sansar D et al (2007) Staging and resection of lung cancer with minimal invasion of the adjacent lobe. Eur J Cardiothorac Surg 32:855-858
20. Kim AW, Faber LP, Warren WH et al (2010) Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg 139:606-611
21. Venuta F, Anile M, Diso D et al (2007) Operative complications and early mortality after induction therapy for lung cancer. Eur J Cardiothorac Surg 31:714-717
22. Martin J, Ginsberg RJ, Abolhoda A et al (2001) Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72:1149-1154
23. Mansour Z, Kochetkova EA, Santelmo N et al (2009) Risk factors for early mortality and morbidity after pneumonectomy: a reappraisal. Ann Thorac Surg 88:1737-1743